Evaluation of LIAISON Treponema Screen, a Novel Recombinant Antigen-Based Chemiluminescence Immunoassay for Laboratory Diagnosis of Syphilis

DOI: 10.1128/CDLI.12.10.1231-1234.2005

Article Figures & Data

TABLE 1.

RPR and treponemal test reactivities detected in the panel of negative control sera^a

Specimen category (no. of samples)	% Reactivity (no. of samples reactive or equivocal/total no. tested)
Specimen category (no. of samples)	RPR	CLIA	EIA	TPHA	WB
Blood donors (2494)	2.77 (69/2,494)	0.12 (3/2,494)	0.04 (1/2,494)	0	0.04 (1/2,494)
Lyme disease (30)	0	0	0	3.33 (1/30)	0
Streptococcus pyogenes infection (10)	10 (1/10)	0	0	0	0
Mononucleosis (10)	10 (1/10)	0	0	0	0
Pregnant women (5)	20 (1/5)	0	0	0	0
ANA positive (16)	12.5 (2/16)	0	0	0	0
RF positive (10)	10 (1/10)	0	0	0	0
T. denticola positive (15)	0	0	0	0	0
Total (2,590)	2.90 (75/2,590)	0.12 (3/2,590)	0.04 (1/2,590)	0.04 (1/2,590)	0.04 (1/2,590)

↵a Treponemal tests used were LIAISON Treponema Screen, syphilis screening recombinant EIA, TPHA, and WB. Negative control sera were samples from blood donors and cross-reacting samples. ANA, antinuclear antibody; RF, rheumatoid factor.

TABLE 2.

Test reactivities in relation to stage of syphilis and treatment status

Stage of disease and treatment status (no. of samples)	% Reactivity (no. of samples reactive/total no. tested)^a
Stage of disease and treatment status (no. of samples)	CLIA	EIA	TPHA	WB	RPR
Untreated primary (7)	100	57.1 (4/7)	57.1 (4/7)	100	85.7 (6/7)
Untreated secondary (31)	100	100	100	100	96.8 (30/31)
Treated latent (77)	98.7 (76/77)	96.1 (74/77)	96.1 (74/77)	100	6.5 (5/77)
Untreated cardiovascular (5)	100	100	100	100	100
Untreated neurosyphilis (6)	100	100	100	100	100
Untreated congenital (5)	100	100	100	100	100
Total (131)	99.2 (130/131)	95.4 (125/131)	94.7 (124/131)	100	43.5 (57/131)

↵a Tests compared were LIAISON Treponema Screen, syphilis screening recombinant EIA, TPHA, WB, and RPR.

Test	% Sensitivity	% Specificity
LIAISON Treponema Screen	99.2	99.9
Syphilis screening recombinant EIA	95.4	99.9
TPHA	94.7	99.9
WB	100	99.9
RPR^a	96.3	97.1